ze 50-0134
Small moleculeexperimental
Clinical trial activity
3 trials · 2 clinical orgs · 0 marketing orgs
Phase 1
3
Phase 2
0
Phase 3
0
Phase 4
0
Earliest trial started May 21, 2024 (NCT06787131)
Timeline
2020s
- Jan 1, 2024
Earliest Phase 1 Sponsor(trial)
Indications
Mechanism of action
- Apoptosis regulator Bcl-2INHIBITOR
BCL2 inhibitor
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT07303660 | Phase 1 | Jan 10, 2026 | Lomond Therapeutics Holdings, Inc. |
| NCT06708897 | Phase 1 | Jan 31, 2025 | Eilean Therapeutics |
| NCT06787131 | Phase 1 | May 21, 2024 | Eilean Therapeutics |
Showing 3 of 3 trials
Page 1 / 1
Organizations
Research & Development (2)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Eilean Therapeutics | For profit | 2 | 2 | 1 | 2024 |
| Lomond Therapeutics Holdings, Inc. | For profit | 1 | 1 | 1 | 2026 |
2 organizations
Page 1 / 1